TrialThe Lancet. Oncology2022

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Andrew R Clamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.